[18F]2-fluoro-2-deoxy-sorbitol ([18F]FDS) PET imaging repurposed for quantitative estimation of blood-brain barrier permeability in a rat model of Alzheimer's disease
Annales Pharmaceutiques Françaises · 2024
DOI: 10.1016/j.pharma.2024.04.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annales Pharmaceutiques Françaises, 2024. Verfasst von Amélie Soyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Service hospitalier Frédéric-Joliot, laboratoire d'imagerie biomédicale multimodale (BioMaps), Inserm, CNRS, CEA, université Paris-Saclay, 91401 Orsa…. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Alzheimer Disease, Positron-Emission Tomography, Disease Models, Animal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Numerous studies suggest that blood-brain barrier (BBB) dysfunction may contribute to the progression of Alzheimer's disease (AD). Clinically available neuroimaging methods are needed for quantitative "scoring" of BBB permeability in AD patients. [18F]2-fluoro-2-deoxy-sorbitol ([18F]FDS), which can be easily obtained from simple chemical reduction of commercial [18F]2-fluoro-2-deoxy-glucose ([18F]FDG), was investigated as a small-molecule marker of BBB permeability, in a pre-clinical model of AD using in vivo PET imaging. Chemical reduction of [18F]FDG to [18F]FDS was obtained with a 100% conversion yield. Dynamic PET acquisitions were performed in the APP/PS1 rat model of AD (TgF344-AD, n=3) compared with age-matched littermates (WT, n=4). The brain uptake of [18F]FDS was determined in selected brain regions, delineated from a coregistered rat brain template. The brain uptake of [18F]FDS in the brain regions of AD rats versus WT rats was compared using a 2-way ANOVA. The uptake of [18F]FDS was significantly higher in the whole brain of AD rats, as compared with WT rats (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service hospitalier Frédéric-Joliot, laboratoire d'imagerie biomédicale multimodale (BioMaps), Inserm, CNRS, CEA, université Paris-Saclay, 91401 Orsay, France.
- Centre d'études de Saclay, CEA, CNRS, NeuroSpin/BAOBAB, Paris-Saclay University, 91191 Gif-sur-Yvette, France.
- Service hospitalier Frédéric-Joliot, laboratoire d'imagerie biomédicale multimodale (BioMaps), Inserm, CNRS, CEA, université Paris-Saclay, 91401 Orsay, France. Electronic address: nicolas.tournier@cea.fr.
Zitieren
APA
Soyer, A., Goutal, S., Leterrier, S., Marie, S., Larrat, B., Selingue, E., Winkeler, A., Sarazin, M., Bottlaender, M., & Tournier, N. (2024). [18F]2-fluoro-2-deoxy-sorbitol ([18F]FDS) PET imaging repurposed for quantitative estimation of blood-brain barrier permeability in a rat model of Alzheimer's disease. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2024.04.004
Vancouver
Soyer A, Goutal S, Leterrier S, Marie S, Larrat B, Selingue E, et al. [18F]2-fluoro-2-deoxy-sorbitol ([18F]FDS) PET imaging repurposed for quantitative estimation of blood-brain barrier permeability in a rat model of Alzheimer's disease. Annales Pharmaceutiques Françaises. 2024. doi:10.1016/j.pharma.2024.04.004
BibTeX
@article{Soyer2024,
author = {Soyer, Amélie and Goutal, Sébastien and Leterrier, Sarah and Marie, Solène and Larrat, Benoit and Selingue, Erwan and Winkeler, Alexandra and Sarazin, Marie and Bottlaender, Michel and Tournier, Nicolas},
title = {[18F]2-fluoro-2-deoxy-sorbitol ([18F]FDS) PET imaging repurposed for quantitative estimation of blood-brain barrier permeability in a rat model of Alzheimer's disease},
journal = {Annales Pharmaceutiques Françaises},
year = {2024},
doi = {10.1016/j.pharma.2024.04.004}
}
EUVIMED